

## June 7, Friday

### Symposium 7 (Dainippon Sumitomo Pharma Co., Ltd./Genzyme Japan K.K.)

#### 9:00-10:00 Session-7 Recent Advance in Fabry Disease

*Chairs: Ichiei Narita; Yukio Yuzawa*

#### 9:00- 9:20 Recent Advance in Fabry Disease: Over View

*Speaker: David G. Warnock*

University of Alabama at Birmingham, Birmingham, Alabama, USA

#### 9:20- 9:40 Prevalence of Fabry Disease in Japanese Dialysis Patients

*Speaker: Eiji Kusano*

Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Tochigi, Japan

#### 9:40-10:00 Enzyme Replacement Therapy for Fabry Disease

*Speaker: Michael L. West*

Division of Nephrology, Department of Medicine, Faculty of Medicine, Dalhousie University, Halifax, Canada

### Symposium 8

#### 10:20-11:40 Session-8 The Effects of Lipid-Lowering Treatment on Proteinuria and CKD Progression

*Chairs: Jonathan Craig; Yasuhiko Iino*

#### 10:20-10:40 Effects of Pitavastatin (Livalo) on eGFR in Hypercholesterolemic Patients with CKD: Livalo Effectiveness and Safety Study (LIVES)

*Speaker: Kenjiro Kimura*

Department of Nephrology and Hypertension, Internal Medicine, St. Marianna University School of Medicine, Kanagawa Japan

#### 10:40-11:00 Effect of Atorvastatin for the progression of CKD (ASUCA Study)

*Speaker: Masato Kasahara*

EBM Research Center, Kyoto University, Kyoto, Japan

#### 11:00-11:20 The role of syndecan-1 in proteinuric dyslipidaemia; evidence from renal transplantation and the PREVEND study

*Speaker: Stephan Bakker*

Division of Nephrology, Department of Medicine, University Medical Center Groningen Groningen, Netherlands

11:20-11:40 **Effect of lipid lowering drugs on proteinuria: Overview**

***Speaker: Vito Campese***

Division of Nephrology, Keck School of Medicine, University of Southern California, Los Angeles, USA

## **Lunch and Luncheon Seminar 2 (KANEKA MEDIX CORPORATION)**

12:00-12:40 **Luncheon Seminar-2 Beneficial Effect of LDL-apheresis in Refractory Nephrotic Syndrome**

***Chair: Shunya Uchida***

***Speaker: Eri Muso***

Department of Nephrology and Dialysis, The Tazuke Kofukai Medical Research Institute, Kitano Hospital, Osaka, Japan

## **Symposium 9**

13:00-14:00 **Session-9 Effects of Lipid-Lowering Treatment on CVD in CKD(1)**

***Chairs : Christoph Wanner; Tetsuo Shoji (Pfizer Japan Inc.)***

13:00-13:20 **The ALERT Trial**

***Speaker: Hallvard Holdaas***

Rikshospitalet, Oslo, Norway.

13:20-13:40 **Results of the 4D Study: 10 Year Follow-Up**

***Speaker: Christoph Wanner***

Division of Nephrology, Department of Medicine, University of Wurzburg, Wurzburg, Germany

13:40-14:00 **The AURORA Trial**

***Speaker: Bengt Fellström***

Department of Medical Science, Renal Unit, University Hospital, Uppsala, Sweden

## **Symposium 10**

14:20-15:40 **Session-10 Effects of Lipid-Lowering Treatment on CVD in CKD(2)**

***Chairs : Bertram L. Kasiske; Yusuke Tsukamoto***

14:20-14:40 **Results of the SHARP Study**

***Speaker: Jonathan Craig***

The Center for Kidney Research, The Children's Hospital at Westmead, Sydney, Australia

14:40-15:00 **Meta-Analysis of Statins in CKD Patients**

***Speaker: Ashish Upadhyay***

Division of Nephrology, Department of Medicine, School of Medicine, Boston University, Boston, USA

15:00-15:20 **Effects of Fibrate in Kidney Disease**

***Speaker: Min Jun***

Division of Nephrology, Department of Medicine, University of Calgary, Alberta, Canada

15:20-15:40 **Summary of KDIGO Guideline**

***Speaker: Christoph Wanner***

Division of Nephrology, Department of Medicine, University of Wurzburg, Wurzburg,  
Germany

## **Closing**

15:40-16:00 **Wrap-up and Closing Remarks**

***Speakers: Bertram L. Kasiske and Takao Saito***